Warts
Conditions
Brief summary
To evaluate whether laser was superior to cryotherapy for recalcitrant warts
Detailed description
Patients with recalcitrant warts were randomized equally to receive laser or cryotherapy every 3 to 4 weeks, for a maximum of 4 sessions.The primary outcomes were the cure rate at 16 weeks; secondary outcomes included time to clearance of warts, patient satisfaction with the treatment and treatment-related adverse effects.
Interventions
OTHERlaser treatment
a maximum of 4 sessions, with an interval of 3 to 4 weeks
OTHERcryotherapy
a maximum of 4 sessions, with an interval of 3 to 4 weeks
Sponsors
The 306 Hospital of People's Liberation Army
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with HPV2/27/57-induced recalcitrant warts, including periungualor mosaic warts, common or plantar warts with a duration of longer than 1 year, and common or plantar warts previously received no more than two sessions of cryotherapy * Total number of warts is ≤10 . * Aged 18 years or older.
Exclusion criteria
* Patients are currently participating in another trial for the treatment of cutaneous warts. * Patients have taken immunosuppressant drugs (such as oral corticosteroids) during the past three months. * Patients have impaired healing eg due to diabetes, vitamin A deficiency, hyperthyroidism and hypothyroidism. * Patients have autoimmune diseases (such as systemic lupus erythematosus, dermatomyositis, scleroderma or other diseases). * Patients are pregnant or ready for pregnancies or breast-feeding. * Patients have cold intolerance (such as cold urticaria, cryoglobulinaemia, cold agglutinin syndrome or Raynaud's syndrome). * Patients have local pain intolerance. * Patients have local hypoesthesia. * Patients are unable to tolerate laser or cryotherapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| cure rate at 16 weeks | 16 weeks since the initial treatment | A patient was considered to be cured if all warts were no longer visible and could not be palpated anymore. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| time to clearance of warts | 16 weeks since the initial treatment | The time from treatment initiation until clearance of all warts |
| patient satisfaction with the treatment | 16 weeks since the initial treatment | Patient satisfaction was rated on a 5-point scale (from very happy to very unhappy) |
| treatment-related adverse events | 16 weeks since the initial treatment | Some adverse effects, including pain, swelling, blisters, hemorrhagic bullae, bruising, and skin breakdown, were recorded by the patients, whereas others, including secondary bacterial infection, hyperpigmentation, hypopigmentation, and scarring were evaluated by a dermatologist |
Contacts
Primary ContactShichao Lu, MD
Outcome results
None listed